29 results on '"Yabe, Michitoshi"'
Search Results
2. Effect of polypharmacy on the outcomes of older patients with advanced non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors: A retrospective cohort study
3. Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
4. Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer
5. Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor–Positive Non‐Small Cell Lung Cancer.
6. Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study.
7. Exploring the Relationship Between Anorexia and Therapeutic Efficacy in Advanced Lung Cancer Treatment: A Retrospective Study
8. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma
9. Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy
10. Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer
11. Delayed iliopsoas abscess following COVID-19 pneumonia
12. Prognostic impact of postoperative recurrence in patients with epidermal growth factor receptor-positive non-small cell lung cancer.
13. Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer
14. Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [ComirnatyⓇ])
15. Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer
16. Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer
17. Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors
18. Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
19. Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation
20. Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer
21. Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis
22. MO21-1 Prognostic value of pneumonitis after durvalumab in locally-advanced non-small cell lung cancer
23. Impact of Cancer Cachexia on Treatment With PD-1/PD-L1 Inhibitors Plus Chemotherapy in Advanced Non-small-Cell Lung Cancer
24. Impact of prior ALK-tyrosine kinase inhibitor on pemetrexed-based chemotherapy in patients with advanced ALK positive non-small cell lung cancer.
25. Long-Term Survival in Extensive Disease Small Cell Lung Cancer Patients Treated Without Immune Checkpoint Inhibitors
26. Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression
27. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma
28. A Case of Lung Adenocarcinoma with Bilateral Progressive Sensorineural Hearing Loss due to Meningeal Carcinomatosis
29. Acute exacerbation of combined pulmonary fibrosis and emphysema due to suspected loxoprofen‐induced lung injury.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.